Sangamo Therapeutics, Inc. Common Stock

SGMO Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
SGMO Income Statement
SGMO Balance Sheet
SGMO Cash Flow
Congress Trading

Recent trades of SGMO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
SGMO Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
SGMO Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SGMO Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by SGMO's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

  • $20,000 Jul 20, 2022 Issue: None
  • $20,000 Apr 20, 2022 Issue: None
  • $30,000 Jan 20, 2022 Issue: None
  • $30,000 Oct 20, 2021 Issue: None
  • $27,000 Jul 21, 2021 Issue: None
  • $27,000 Jun 22, 2021 Issue: Medical/Disease Research/Clinical Labs
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof Nov. 12, 2024
  • Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene Jul. 23, 2024
  • Patent Title: Engineering aav May. 14, 2024
  • Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 05, 2024
  • Patent Title: Methods and compositions for the treatment of lysosomal storage diseases Feb. 13, 2024
  • Patent Title: Methods and compositions for regulation of transgene expression Jan. 02, 2024
  • Patent Title: Method for the treatment of mucopolysaccharidosis type i Jan. 02, 2024
  • Patent Title: Regulation of gene expression using engineered nucleases Dec. 19, 2023
  • Patent Title: Engineered target specific base editors Dec. 05, 2023
  • Patent Title: Engineered target specific nucleases Nov. 28, 2023
  • Patent Title: Methods and compositions for engineering immunity Oct. 24, 2023
  • Patent Title: Artificial nucleases comprising engineered cleavage half-domains Aug. 15, 2023
  • Patent Title: Separation and quantification of empty and full viral capsid particles Aug. 15, 2023
  • Patent Title: Methods and compositions for treating huntington's disease Aug. 15, 2023
  • Patent Title: Compositions and methods for producing recombinant aav Aug. 08, 2023
  • Patent Title: Delivery of target specific nucleases Jul. 04, 2023
  • Patent Title: Dna-binding proteins and uses thereof May. 30, 2023
  • Patent Title: Genetic modification of cytokine inducible sh2-containing protein (cish) gene May. 30, 2023
  • Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene May. 23, 2023
  • Patent Title: Targeted integration into the ppp1r12c locus May. 16, 2023
  • Patent Title: Methods and compositions for gene inactivation May. 16, 2023
  • Patent Title: Methods and compositions for regulation of transgene expression May. 02, 2023
  • Patent Title: Methods and compositions for treating hemophilia Apr. 25, 2023
  • Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 21, 2023
  • Patent Title: Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder Feb. 28, 2023
  • Patent Title: Targeted disruption of t cell and/or hla receptors Nov. 29, 2022
  • Patent Title: Tau modulators and methods and compositions for delivery thereof Nov. 22, 2022
  • Patent Title: Methods and compositions for treatment of a genetic condition Nov. 08, 2022
  • Patent Title: Liver-specific constructs factor viii expression cassettes and methods of use thereof Sep. 27, 2022
  • Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Sep. 13, 2022
  • Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Aug. 23, 2022
  • Patent Title: Engineered target specific nucleases Aug. 02, 2022
  • Patent Title: Targeted disruption of the t cell receptor Jun. 07, 2022
  • Patent Title: Methods and compositions for targeted cleavage and recombination Apr. 26, 2022
  • Patent Title: Targeted disruption of the mhc cell receptor Mar. 29, 2022
  • Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Mar. 22, 2022
  • Patent Title: T cell modifying compounds and uses thereof Feb. 01, 2022
  • Patent Title: Methods and compositions for modulating pd1 Feb. 01, 2022
  • Patent Title: Methods and compositions for the treatment of fabry disease Jan. 11, 2022
  • Patent Title: Methods and compositions for targeted single-stranded cleavage and targeted integration Oct. 19, 2021
  • Patent Title: Artifical nucleases comprising engineered cleavage half-domains Oct. 05, 2021
  • Patent Title: Htt repressors and uses thereof Sep. 21, 2021
  • Patent Title: Methods and compositions for treating huntington's disease Sep. 07, 2021
  • Patent Title: Compositions for linking dna-binding domains and cleavage domains Jun. 22, 2021
  • Patent Title: Method for the treatment of lysosomal storage diseases Jun. 22, 2021
  • Patent Title: Gene correction of scid-related genes in hematopoietic stem and progenitor cells Jun. 01, 2021
  • Patent Title: Engineered target specific nucleases Apr. 13, 2021
  • Patent Title: Methods and compositions for regulation of transgene expression Apr. 13, 2021
  • Patent Title: Methods and compositions for genome engineering Apr. 06, 2021
  • Patent Title: Modulation of liver genes Mar. 30, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of SGMO in WallStreetBets Daily Discussion

SGMO News

Recent insights relating to SGMO

CNBC Recommendations

Recent picks made for SGMO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SGMO

SGMO Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SGMO Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top